1515
Annons

Nanoform launches technology for biologics and sets new near-term business target for 2021

Inside information

Nanoform Finland Plc

November 27th, 2020 at 07:50 a.m. Finnish time

Nanoform launches technology for biologics and sets new near-term business target for 2021

Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, today announced a proprietary technology that can form biological nanoparticles as small as 50 nm and announced a new near-term business target for 2021 to deliver its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner.

As drug molecules become more complex so do the options to deliver them. This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. The technology is in its early stages of development and a patent application has recently been filed with the US Patent Office for the technology. As of today, Nanoform has two non-GMP lines on the biologics side in addition to the eight CESS® small molecule nanoparticle technology non-GMP lines.

Prof. Edward Hæggström, Nanoform CEO: “Small is powerful, also in Bio! We are committed to improving patients’ lives and supporting our pharmaceutical partners in developing the best medicines possible. Having established our CESS® small molecule nanoparticle technology to GMP, we continue to focus on delivering value for our partners and now we can extend our partnerships into supporting their biological programs. There are significant challenges in drug development in this space and we look forward to working closely with pharma and biotech partners to discover how we can add value to their programs, provide patient benefit and competitive product differentiation.”

Prof. Niklas Sandler, Nanoform CTO: “We have for several years been developing this new exciting technology for Biologics, side by side with our CESS® small molecule nanoparticle technology, and it is with great excitement we now start to introduce it to our pharma partners. Potential applications could be in improving delivery route, uptake, and drug loading capacity in formulations and in enabling new drug combinations, tailoring of release profiles, and implementing lighter infrastructure for drug logistics.”

Christian Jones, Nanoform CCO: “It is rare for any company to bring to market two groundbreaking platform technologies that could open up significant opportunities for the global pharma industry. I am delighted we are introducing this early development nanoparticle technology in the field of biologics as there are so many areas where nanoparticles can add value in this hugely promising but significantly challenging space. We look forward to exploring the potential advantages with our Pharma and Biotech partners in the hope we can together make better medicines for patients.”

Telephone conference for analysts, investors, and media:

In connection with this release and Nanoform’s Q3 report release (Nov 27th at 08.00 a.m. Helsinki time) Nanoform will hold a conference call and online presentation today Friday November 27th at 15.00 p.m. Helsinki time (14.00 p.m. Stockholm time). Nanoform will be represented by CEO Edward Hæggström, CFO Albert Hæggström, CTO Niklas Sandler, CCO Christian Jones and CBO Gonçalo Andrade. The presentation will be delivered in English.

The presentation will be broadcast live as a webcast available at: https://financialhearings.com/event/13383

Teleconference dial-in numbers:

Finland: +358981710521

Sweden: +46856642692

United Kingdom: +443333009263

United States: +18332498407

For further information, please contact:

Prof. Edward Hæggström, CEO

edward.haeggstrom@nanoform.com / +358 29 370 0150

For investor relations queries, please contact:

Henri von Haartman, Director of Investor Relations

hvh@nanoform.com / +46 7686 650 11

The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on November 27th, 2020 at 07:50 a.m. Finnish time.

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. The Company focuses on reducing attrition in clinical trials and on enhancing drug molecules’ formulation performance through its nanoforming services. Nanoform’s capabilities span the small to large molecule development space and the company focuses on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806. For more information please visit http://www.nanoform.com

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform’s strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform’s business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks specified in Nanoform’s prospectus published (on May 22, 2020) in connection with Nanoform’s initial public offering (the “Prospectus”) under “Risk Factors” and in our other filings or documents furnished to the Finnish Financial Supervisory Authority in connection with the Prospectus. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Följande bilagor finns för nedladdning:
Release

Se fullständigt pressmeddelande och andra nyheter från detta bolag på Cision News.
Vill du också synas med dina nyheter på Di.se?
Läs mer om publicering på Di.se

Gaming Innovation Group signs platform deal with casino operator Kings Media in Ontario

Gaming Innovation Group Inc. (GiG) has today signed an agreement with new strategic partner Kings Media Ltd, best known for operating the ‘King Billy’ casino brand across .com markets, marking its arrival into the newly regulated Ontario province in Canada.

The deal will see GiG provide its award winning platform and represents a continued strengthening of a targeted strategy to leverage GiG’s extensive experience in fast growing, complex regulated jurisdictions. The partnership is also notable as Kings Media’s first venture into North American markets, affirming GiG’s assertion that its platform and solutions are perfectly suited for similar online challengers keen to access and expand into regulated regions.

The agreement has been signed for an initial three-year period with the opportunity to be further renewed. It is expected that, with decades of operational experience, the team from Kings Media will be able to call on their significant understanding within the Casino industry, helping to successfully launch and power the brand towards growth in Ontario. 

The Canadian province of Ontario opened for iGaming as recently as April 2022 and is expected to grow to €2bn in gross gaming revenue (GGR) over the next three years, according to H2 Gambling Data. This will be the second deal in Ontario for GiG, with an existing customer expected to launch this quarter, with King Media expected to go live in H1 2023. 

Volodymyr Harkusha, CEO of Kings Media Ltd, said: “In our quest to expand to the exponentially competitive Ontario market, we were looking for an industry-leading, future-ready partner. GiG fit the bill perfectly, not only by ticking and double-ticking all the boxes, but also by impressing us with their clear vision and dedication to the project. We are looking forward to working together with GiG on the mutual challenges ahead and we are certain that this collaboration will enable us to gain a significant foothold in the Ontario market.

Richard Brown, CEO of GiG, said: “I am particularly delighted to partner with Kings Media, a prominent online casino operator and brand with a great deal of experience, who share our values around personalisation, responsible gaming and the importance of regulated markets.  We see great potential in Ontario, particularly when we can harness the operational experience of operators like Kings Media. We look forward to working closer with the team to maximise potential through a successful launch into the market, and anticipate this to become a successful client for GiG.

For more information:
Richard Brown, CEO GiG, richard.brown@gig.com, +34 661599025
 

About Gaming Innovation Group (GiG)
Gaming Innovation Group is a leading iGaming technology company, providing solutions, products and services to iGaming Operators. Founded in 2012, Gaming Innovation Group’s vision is ‘To be the industry-leading platform, sportsbook and media provider delivering world-class solutions to our iGaming partners and their customers.  GiG’s mission is to drive sustainable growth and profitability of our partners through product innovation, scalable technology and quality of service. Gaming Innovation Group operates out of Malta and is dual-listed on the Oslo Stock Exchange under the ticker symbol GIG and on Nasdaq Stockholm under the ticker symbol GIGSEK. www.gig.com 
 

About Kings Media
Kings Media is the parent company of King Billy Casino, one of the fastest growing and most awarded online operators in the world. King Billy, launched in 2017, has had more than 20 awards and distinctions in its 5-year history, including AskGamblers Best New Casino, AskGamblers Best Casino, iGB Awards Best Affiliate Program and several short-lists for its customer services and marketing campaigns. The casino, which is available in 4 languages (English, French, German and Japanese), has created a superb user experience around the myth of King Billy and his Kingdom and treats all its players with the respect and attention they deserve. King Billy's motto: “Play Long & Prosper!”.

Följande bilagor finns för nedladdning:
Release

Se fullständigt pressmeddelande och andra nyheter från detta bolag på Cision News.
Vill du också synas med dina nyheter på Di.se?
Läs mer om publicering på Di.se

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1090kr
Prenumerera